81 180

Cited 0 times in

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study

DC Field Value Language
dc.contributor.author김지형-
dc.contributor.author김혜련-
dc.contributor.author안병철-
dc.contributor.author임선민-
dc.contributor.author조병철-
dc.contributor.author표경호-
dc.contributor.author홍민희-
dc.contributor.author김혜련-
dc.contributor.author안병철-
dc.contributor.author임선민-
dc.contributor.author조병철-
dc.contributor.author표경호-
dc.contributor.author홍민희-
dc.date.accessioned2021-09-29T01:35:08Z-
dc.date.available2021-09-29T01:35:08Z-
dc.date.issued2021-07-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/184441-
dc.description.abstractUp to 40% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) may develop central nervous system (CNS) metastases throughout their disease. Moreover, the first- and second-generation EGFR-tyrosine kinase inhibitors have limited efficacy because of their poor blood–brain barrier permeability. Therefore, we conducted preplanned analyses of ASTRIS, a clinical study of the third-generation EGFR-TKI osimertinib to demonstrate its potential role in intracranial response efficacies. We retrospectively examined 89 NSCLC patients with brain evaluation who were not amenable to curative surgery or radiotherapy and received osimertinib upon confirmation of the presence of the T790M mutation. We collected the information regarding patients’ baseline characteristics, baseline intracranial status, including leptomeningeal metastases (LM), and intracranial responses measured by Response Evaluation Criteria in Solid Tumors version 1.1, using independent central review. The median age was 60 years, and 69.7% of the patients were female. Sixty-five patients (73.0%) had brain metastases (BM) at baseline and nineteen patients (23.5%) had additional LM. Among patients with brain metastases, 24 (36.9%) had ≥1 measurable brain metastases and 16 were evaluated for the objective response. In the CNS evaluable for response set, the intracranial objective response rate (cORR) and disease control rate (cDCR) were 62.5% (95% confidence interval (CI), 38.3–82.6%) and 93.8% (95% CI, 74.3–99.3%), respectively. The median intracranial progression-free survival (cPFS) was 13.0 (95% CI, 7.21–18.8) months, including patients with measurable and non-measurable BM or LM. Our cORR, cDCR, and cPFS were comparable to those observed in previous clinical trials. The outcome of this study helps to demonstrate the potential role of intracranial efficacies of osimertinib 80 mg administration in T790M-positive advanced NSCLC with/without BM or LM. View Full--
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfCANCERS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleAnalyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorBeung-Chul Ahn-
dc.contributor.googleauthorJee Hung Kim-
dc.contributor.googleauthorKyoung-Ho Pyo-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorMin Hee Hong-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi10.3390/cancers13153681-
dc.contributor.localIdA00999-
dc.contributor.localIdA01166-
dc.contributor.localIdA05556-
dc.contributor.localIdA03369-
dc.contributor.localIdA03822-
dc.contributor.localIdA04809-
dc.contributor.localIdA04393-
dc.contributor.localIdA01166-
dc.contributor.localIdA05556-
dc.contributor.localIdA03369-
dc.contributor.localIdA03822-
dc.contributor.localIdA04809-
dc.contributor.localIdA04393-
dc.relation.journalcodeJ03449-
dc.identifier.eissn2072-6694-
dc.subject.keywordnon-small-cell lung cancer-
dc.subject.keywordepidermal growth factor receptor-
dc.subject.keywordosimertinib-
dc.subject.keywordintracranial response-
dc.contributor.alternativeNameKim, Jee Hung-
dc.contributor.affiliatedAuthor김지형-
dc.contributor.affiliatedAuthor김혜련-
dc.contributor.affiliatedAuthor안병철-
dc.contributor.affiliatedAuthor임선민-
dc.contributor.affiliatedAuthor조병철-
dc.contributor.affiliatedAuthor표경호-
dc.contributor.affiliatedAuthor홍민희-
dc.contributor.affiliatedAuthor김혜련-
dc.contributor.affiliatedAuthor안병철-
dc.contributor.affiliatedAuthor임선민-
dc.contributor.affiliatedAuthor조병철-
dc.contributor.affiliatedAuthor표경호-
dc.contributor.affiliatedAuthor홍민희-
dc.citation.volume13-
dc.citation.number15-
dc.citation.startPage3681-
dc.identifier.bibliographicCitationCANCERS, Vol.13(15) : 3681, 2021-07-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.